Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Inflammatory and immune checkpoint signatures in thyroid cancer: IHC profiling of IL-6 and its inducer PDL1 distinguishes histopathological subtypes and reflects tumor aggressiveness.

Created on 02 Nov 2026

Authors

Sherine Refat, Amal Abd El Hafez, Maryan Waheeb Fahmi, Salma Elashwah, Reham Mohamed Nagib, Shaimaa M Yussif, Rehab Talaat

Published in

Journal of immunoassay & immunochemistry. Pages 1-20. Nov 01, 2026. Epub Nov 01, 2026.

Abstract

This retrospective cross-sectional study evaluated the immunohistochemical (IHC) expression of interleukin‑6 (IL-6) and programmed death ligand 1 (PDL1) in thyroid carcinoma (TC; 100 cases) versus non-neoplastic/benign thyroid lesions (15 cases). IL-6 and PDL1 were assessed on tissue microarrays using an immunoreactive score (low < 6 or high ≥ 6). IL-6 and PDL1 positivity was significantly higher in TCs (IL-6: 57% vs 6.7%; PDL1: 60% vs 0%; both p ≤ 0.001). High IL-6 occurred in 39% of TCs and was associated with older age, papillary and oncocytic TCs, lymphovascular and capsular invasion, extrathyroidal extension, advanced TNM stage, multifocality, nodal metastasis, and recurrence (all p ≤ 0.05). High PDL1 occurred in 36% of TCs, was most frequent in papillary, anaplastic and oncocytic TCs, and was associated with older age, larger tumors, higher T and TNM stage, multifocality, lymphovascular emboli, extrathyroidal extension, and nodal positivity (all p ≤ 0.05). IL-6 and PDL1 showed a moderate positive correlation (r = 0.486, p ≤ 0.001). IL-6 and PD-L1 expression was significantly higher in TCs than in benign/non-neoplastic thyroid lesions and was significantly associated with biologically aggressive TCs, suggesting their potential diagnostic and prognostic utility. Their coordinated overexpression supports IL-6/PDL1 axis activation as a hallmark of high-risk TC and a potential target for combined immunomodulatory strategies.

PMID:
42968489
Bibliographic data and abstract were imported from PubMed on 02 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement